Skip to main content
Erschienen in:

01.08.2007 | Leitthema

„Active surveillance“ des lokalisierten Prostatakarzinoms

verfasst von: K. Czeloth, Prof. Dr. P. Albers

Erschienen in: Die Onkologie | Ausgabe 8/2007

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die Strategie einer aktiven Überwachung („active surveillance“) des lokalisierten Prostatakarzinoms mit selektiver, verzögerter Intervention könnte grundsätzlich für viele Patienten eine Alternative zur sofortigen kurativen Therapie (radikale Prostatektomie oder Strahlentherapie) darstellen. Im Gegensatz zur aus Patientensicht immer stärker werdenden Forderung nach dieser Option stehen jedoch die noch relativ spärlichen prospektiven Daten zu einer solchen Strategie. Es ist immer noch unklar, wie die Patienten selektiert werden sollen und welche Kriterien für einen Abbruch der Überwachung und die Empfehlung einer Intervention angewendet werden sollen. Bevor die Option der „active surveillance“ eine wirkliche Alternative zur kurativen Therapie darstellt, müssen aktuell initiierte prospektive Studien beendet sein. So lange sollten Patienten für diese Therapiemöglichkeit eher strenger selektiert und engmaschiger überwacht werden.
Literatur
1.
Zurück zum Zitat Albertsen PC, Hanley JA, Gleason DF, Barry MJ (1998) Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 280: 975–980PubMedCrossRef Albertsen PC, Hanley JA, Gleason DF, Barry MJ (1998) Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 280: 975–980PubMedCrossRef
2.
Zurück zum Zitat Albertsen PC, Hanley JA, Fine J (2005) 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 293(17): 2095–2101PubMedCrossRef Albertsen PC, Hanley JA, Fine J (2005) 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 293(17): 2095–2101PubMedCrossRef
3.
Zurück zum Zitat Albertsen PC, Hanley JA, Penson DF et al. (2007) 13-year outcomes following treatment for clinically localized prostate cancer in a population based cohort. J Urol 177(3): 932–936PubMedCrossRef Albertsen PC, Hanley JA, Penson DF et al. (2007) 13-year outcomes following treatment for clinically localized prostate cancer in a population based cohort. J Urol 177(3): 932–936PubMedCrossRef
4.
Zurück zum Zitat Becker N (2003) Epidemiological aspects of cancer screening in Germany. J Cancer Res Clin Oncol 129(12): 691–702PubMedCrossRef Becker N (2003) Epidemiological aspects of cancer screening in Germany. J Cancer Res Clin Oncol 129(12): 691–702PubMedCrossRef
5.
Zurück zum Zitat Bill-Axelson A, Holmberg L, Ruutu M et al. (2005) Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 12;352(19): 1977–184 Bill-Axelson A, Holmberg L, Ruutu M et al. (2005) Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 12;352(19): 1977–184
6.
Zurück zum Zitat Breslow N, Chan CW, Dhom G et al. (1977) Latent carcinoma of prostate at autopsy in seven areas. The International Agency for Research on Cancer, Lyons, France. Int J Cancer. 20(5): 680–688 Breslow N, Chan CW, Dhom G et al. (1977) Latent carcinoma of prostate at autopsy in seven areas. The International Agency for Research on Cancer, Lyons, France. Int J Cancer. 20(5): 680–688
7.
Zurück zum Zitat Carter HB, Ferrucci L, Kettermann A et al. (2006) Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst 98(21): 1521–1527PubMedCrossRef Carter HB, Ferrucci L, Kettermann A et al. (2006) Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst 98(21): 1521–1527PubMedCrossRef
8.
Zurück zum Zitat Carter CA, Donahue T, Sun L et al. (2003) Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low-risk localized prostate cancer in the prostate-specific antigen era. J Clin Oncol 21(21): 4001–4008PubMedCrossRef Carter CA, Donahue T, Sun L et al. (2003) Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low-risk localized prostate cancer in the prostate-specific antigen era. J Clin Oncol 21(21): 4001–4008PubMedCrossRef
9.
Zurück zum Zitat Cuzick J, Fisher G, Kattan MW et al. (2006) Long-term outcome among men with conservatively treated localised prostate cancer. Br J Cancer 95(9): 1186–1194PubMedCrossRef Cuzick J, Fisher G, Kattan MW et al. (2006) Long-term outcome among men with conservatively treated localised prostate cancer. Br J Cancer 95(9): 1186–1194PubMedCrossRef
10.
Zurück zum Zitat D’Amico AV, Whittington R, Malkowicz SB et al. (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280(11): 969–974CrossRef D’Amico AV, Whittington R, Malkowicz SB et al. (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280(11): 969–974CrossRef
11.
Zurück zum Zitat D’Amico AV, Cote K, Loffredo M et al. (2003) Determinants of prostate cancer specific survival following radiation therapy during the prostate specific antigen era. J Urol 170(6 Pt 2): S42–46; discussion S46–47CrossRef D’Amico AV, Cote K, Loffredo M et al. (2003) Determinants of prostate cancer specific survival following radiation therapy during the prostate specific antigen era. J Urol 170(6 Pt 2): S42–46; discussion S46–47CrossRef
12.
Zurück zum Zitat D’Amico AV, Chen MH, Roehl KA, Catalona WJ. (2004) Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 351(2): 125–135CrossRef D’Amico AV, Chen MH, Roehl KA, Catalona WJ. (2004) Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 351(2): 125–135CrossRef
13.
Zurück zum Zitat Epstein JI, Chan DW, Sokoll LJ et al. (1998) Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. J Urol 160(6 Pt 2): 2407–2411PubMedCrossRef Epstein JI, Chan DW, Sokoll LJ et al. (1998) Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. J Urol 160(6 Pt 2): 2407–2411PubMedCrossRef
14.
Zurück zum Zitat Evans HS, Moller H (2003) Recent trends in prostate cancer incidence and mortality in southeast England. Eur Urol 43(4): 337–341PubMedCrossRef Evans HS, Moller H (2003) Recent trends in prostate cancer incidence and mortality in southeast England. Eur Urol 43(4): 337–341PubMedCrossRef
15.
Zurück zum Zitat Fenton JJ, Cai Y, Weiss NS et al. (2007) Delivery of cancer screening: how important is the preventive health examination? Arch Intern Med 167(6): 580–585PubMedCrossRef Fenton JJ, Cai Y, Weiss NS et al. (2007) Delivery of cancer screening: how important is the preventive health examination? Arch Intern Med 167(6): 580–585PubMedCrossRef
16.
Zurück zum Zitat Holmberg L, Bill-Axelson A, Helgesen F et al. (2002) A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 347(11): 781–789PubMedCrossRef Holmberg L, Bill-Axelson A, Helgesen F et al. (2002) A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 347(11): 781–789PubMedCrossRef
17.
Zurück zum Zitat Johansson J-E, Andrén O, Andersson S-O et al. (2004) Natural history of Eearly, localized prostate cancer. JAMA 291: 2713–2719PubMedCrossRef Johansson J-E, Andrén O, Andersson S-O et al. (2004) Natural history of Eearly, localized prostate cancer. JAMA 291: 2713–2719PubMedCrossRef
18.
Zurück zum Zitat Khan MA, Carter HB, Epstein JI et al. (2003) Can prostate specific antigen derivatives and pathological parameters predict significant change in expectant management criteria for prostate cancer? J Urol 170: 2274–2278PubMedCrossRef Khan MA, Carter HB, Epstein JI et al. (2003) Can prostate specific antigen derivatives and pathological parameters predict significant change in expectant management criteria for prostate cancer? J Urol 170: 2274–2278PubMedCrossRef
19.
Zurück zum Zitat Klotz L (2005) Active surveillance for prostate cancer: for whom? J Clin Oncol 23(32): 8165–8169PubMedCrossRef Klotz L (2005) Active surveillance for prostate cancer: for whom? J Clin Oncol 23(32): 8165–8169PubMedCrossRef
20.
Zurück zum Zitat Koch K (2003) Information on early cancer diagnosis: what do the patients want? Med Klin 98(7): 400–403CrossRef Koch K (2003) Information on early cancer diagnosis: what do the patients want? Med Klin 98(7): 400–403CrossRef
21.
Zurück zum Zitat Ochiai T, Shimeno H, Mishima K et al. (2007)The relationship between serum prostate specific antigen level and tumor volume persists in the current era. J Urol 177(3): 903–906PubMedCrossRef Ochiai T, Shimeno H, Mishima K et al. (2007)The relationship between serum prostate specific antigen level and tumor volume persists in the current era. J Urol 177(3): 903–906PubMedCrossRef
22.
Zurück zum Zitat Ochiai A, Trpkov K, Yilmaz A et al. (2007)Validation of a prediction model for low volume/low grade cancer: application in selecting patients for active surveillance. J Urol 177(3): 907–910PubMedCrossRef Ochiai A, Trpkov K, Yilmaz A et al. (2007)Validation of a prediction model for low volume/low grade cancer: application in selecting patients for active surveillance. J Urol 177(3): 907–910PubMedCrossRef
23.
Zurück zum Zitat Parker C, Muston D, Melia J et al. (2006) A model of the natural history of screen-detected prostate cancer, and the effect of radical treatment on overall survival. Br J Cancer 94(10): 1361–1368PubMedCrossRef Parker C, Muston D, Melia J et al. (2006) A model of the natural history of screen-detected prostate cancer, and the effect of radical treatment on overall survival. Br J Cancer 94(10): 1361–1368PubMedCrossRef
24.
Zurück zum Zitat Sakr WA, Grignon DJ, Crissman JD et al. (1994) High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20–69: an autopsy study of 249 cases. In Vivo 8(3): 439–443PubMed Sakr WA, Grignon DJ, Crissman JD et al. (1994) High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20–69: an autopsy study of 249 cases. In Vivo 8(3): 439–443PubMed
25.
Zurück zum Zitat Steineck G, Helgesen F, Adolfsson J (2002) Quality of life after radical prostatectomy or watchful waiting. N Engl J Med 347(11): 790–796PubMedCrossRef Steineck G, Helgesen F, Adolfsson J (2002) Quality of life after radical prostatectomy or watchful waiting. N Engl J Med 347(11): 790–796PubMedCrossRef
26.
Zurück zum Zitat Sved PD, Gomez P, Manoharan M et al. (2004) Limitations of biopsy Gleason grade: implications for counseling patients with biopsy Gleason score 6 prostate cancer. J Urol 172(1): 98–102PubMedCrossRef Sved PD, Gomez P, Manoharan M et al. (2004) Limitations of biopsy Gleason grade: implications for counseling patients with biopsy Gleason score 6 prostate cancer. J Urol 172(1): 98–102PubMedCrossRef
27.
Zurück zum Zitat de Vries SH, Postma R, Raaijmakers R et al. (2007) Overall and disease-specific survival of patients with screen-detected prostate cancer in the European randomized study of screening for prostate cancer, section Rotterdam. Eur Urol 51(2): 366–374CrossRef de Vries SH, Postma R, Raaijmakers R et al. (2007) Overall and disease-specific survival of patients with screen-detected prostate cancer in the European randomized study of screening for prostate cancer, section Rotterdam. Eur Urol 51(2): 366–374CrossRef
28.
Zurück zum Zitat Warlick C, Trock BJ, Landis P et al. (2006) Delayed versus immediate surgical intervention and prostate cancer outcome. J Natl Cancer Inst 98(5): 355–357PubMedCrossRef Warlick C, Trock BJ, Landis P et al. (2006) Delayed versus immediate surgical intervention and prostate cancer outcome. J Natl Cancer Inst 98(5): 355–357PubMedCrossRef
29.
Zurück zum Zitat Zhu H, Roehl KA, Antenor JA, Catalona WJ (2005) Biopsy of men with PSA level of 2.6 to 4.0 ng/mL associated with favorable pathologic features and PSA progression rate: a preliminary analysis. Urology 66(3): 547–551PubMedCrossRef Zhu H, Roehl KA, Antenor JA, Catalona WJ (2005) Biopsy of men with PSA level of 2.6 to 4.0 ng/mL associated with favorable pathologic features and PSA progression rate: a preliminary analysis. Urology 66(3): 547–551PubMedCrossRef
Metadaten
Titel
„Active surveillance“ des lokalisierten Prostatakarzinoms
verfasst von
K. Czeloth
Prof. Dr. P. Albers
Publikationsdatum
01.08.2007
Verlag
Springer-Verlag
Erschienen in
Die Onkologie / Ausgabe 8/2007
Print ISSN: 2731-7226
Elektronische ISSN: 2731-7234
DOI
https://doi.org/10.1007/s00761-007-1229-5

Weitere Artikel der Ausgabe 8/2007

Der Onkologe 8/2007 Zur Ausgabe

CME Weiterbildung • Zertifizierte Fortbildung

Kutanes Melanom

Neu im Fachgebiet Onkologie

Verkürzte MRT bei dichtem Brustgewebe: Was bringen sequenzielle Scans?

21.07.2024 Mamma-MRT Nachrichten

Frauen mit dichtem Brustgewebe könnten zusätzlich zum regulären Mammografie-Screening von sequenziellen MRT-Untersuchungen mit verkürztem Protokoll (AB-MRT) profitieren, schlagen US-Radiologen vor.

Informierte Frauen neigen zu späterem Mammografie-Screening

Frauen in ihren 40ern, die über die Vor- und Nachteile des Mammografie-Screenings auf Brustkrebs informiert werden, neigen stärker dazu, den Screeningbeginn nach hinten zu verschieben. Die Mehrheit aber nähme das Angebot an, wie eine US-Studie zeigt.

Endometriose-Subtypen und das Risiko für Ovarialkarzinome

19.07.2024 Ovarialkarzinom Nachrichten

US-Kohortendaten sprechen dafür, dass verschiedene Endometrioseformen unterschiedlich mit dem Risiko für Ovarialkarzinome assoziiert sind. Besonders erhöht ist das Risiko offenbar bei tief infiltrierenden und ovariellen Endometrioseformen.

Die zelluläre Differenzierung wird wiederhergestellt

18.07.2024 Akute myeloische Leukämie Nachrichten

Ivosidenib von Servier ist ein Inhibitor der mutierten Isoform der Isocitrat-Dehydrogenase-1 (IDH1) und wird zur Behandlung von Patientinnen und Patienten mit neu diagnostizierter akuter myeloischer Leukämie (AML) eingesetzt. Die Substanz sorgt für die Wiederherstellung der zellulären Differenzierung.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.